NCT00559299View on ClinicalTrials.gov

Patient Tolerability Study of GSK163090

PHASE1CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions

Depressive Disorder, MajorMajor Depressive Disorder (MDD)

Interventions

DRUG

GSK163090

Trial Locations (1)

67211

GSK Investigational Site, Wichita

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY